Malignant pancreatic neoplasm

Researchers are testing a new CAR-T cell therapy called KD-496 in people with advanced solid tumors, including gastric and pancreatic cancer, that have not responded to at least two prior treatments. The therapy uses a patient's own T cells, which are genetically modified to reco…

This early-stage study tests a vaccine designed to train the immune system to attack cells with a mutated KRAS gene, which is common in pancreatic cancer. The vaccine is given to people at high risk due to family history or pancreatic cysts. The main goals are to see if the vacci…

This early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …

This early-phase trial will test whether adding semaglutide (a GLP-1 drug used for diabetes and weight loss) to standard chemotherapy is safe and tolerable for people with metastatic pancreatic, colorectal, or liver cancer. About 30 participants will receive weekly semaglutide in…

This Phase 3 trial tests whether adding an experimental oral drug called atebimetinib to a modified chemotherapy regimen helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will receive either the new combination or standa…

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This phase II trial is testing whether the drug olaparib can help prevent pancreatic cancer from coming back in people who have already had surgery and chemotherapy and carry a BRCA1, BRCA2, or PALB2 mutation. Olaparib is a targeted therapy that blocks a repair enzyme cancer cell…

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …

This early-phase trial is testing a new oral drug called RMC-5127, alone or combined with other drugs, in adults with advanced solid tumors that have a specific KRAS G12V mutation. The study includes people with lung, colorectal, and pancreatic cancers who have already tried stan…

This trial tests whether adding two drugs (surufatinib and camrelizumab) to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 502 adults who have not had prior treatment for their advanced cancer will be randomly assigned to the new combo or …

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

Researchers are testing an experimental injectable drug called XNW28012 in people with metastatic pancreatic cancer that has worsened after two standard chemotherapy regimens. The phase III trial plans to enroll 226 adults and randomly assigns them in a 2:1 ratio to receive eithe…

This clinical trial is testing a new biological therapy called GAIA-102, alone or combined with the immunotherapy pembrolizumab, for people with advanced stomach or pancreatic cancer that has spread and caused fluid buildup in the abdomen (malignant ascites). The study has two pa…

This study tests a new drug called daraxonrasib in people with pancreatic cancer who have already had surgery and chemotherapy. The goal is to see if taking the drug can delay or prevent the cancer from returning compared to just watching and waiting. About 500 adults will be ran…

This phase II trial tests a treatment called HIPEC, where heated chemotherapy drugs are placed directly into the abdomen during surgery. It is for people with pancreatic cancer that has spread to the lining of the abdomen. The study will enroll 40 participants to see if this appr…

Researchers are testing a new device that uses endoscopic ultrasound to guide microwave energy directly into pancreatic and liver tumors that cannot be removed by surgery. The study enrolls 75 adults with locally advanced or metastatic cancer. The main goal is to see whether the …

This phase 3 trial tests a new drug called daraxonrasib, taken as a pill, either alone or with standard chemotherapy, against chemotherapy alone for people with metastatic pancreatic cancer. About 900 adults with confirmed pancreatic cancer that has spread will be randomly assign…

This pilot study looks at whether closely monitoring and managing blood sugar levels can help people with pancreatic cancer. About 50 participants will wear a continuous glucose monitor during chemotherapy. Half will get intensive glucose management from an endocrinologist, while…

This early-phase trial tests whether injecting a medical glue (Histoacryl®) into the pancreas during Whipple surgery can strengthen the connection between the pancreas and intestine and prevent dangerous leaks. The study involves 30 patients with soft pancreases and narrow ducts,…

Researchers are testing whether giving chemotherapy before surgery helps people with clearly resectable pancreatic head cancer or periampullary cancer live longer than going straight to surgery. The trial enrolls 262 participants and randomly assigns them to either mFOLFIRINOX ch…

This early-phase trial tests a drug called TTI-101 combined with a precise type of radiation (SBRT) in 18 people with pancreatic cancer that is borderline resectable or locally advanced. The goal is to see if the combination is safe and can improve how long patients live without …

Pancreatic ductal adenocarcinoma often returns near where it started, even after surgery. This study tests whether a more thorough operation, called total mesopancreatic excision, can improve local disease control and survival. During pancreaticoduodenectomy, surgeons remove the …

This trial is testing a new type of radiation therapy that adapts daily to the exact shape and position of a pancreatic tumor. The goal is to deliver a high, tumor-killing dose while minimizing damage to nearby stomach and intestines. About 134 people with borderline resectable o…

This study tests whether adding an experimental drug called zoldonrasib to standard chemotherapy helps people with a specific genetic form of metastatic pancreatic cancer (KRAS G12D mutation) live longer without their cancer growing. About 670 adults with advanced pancreatic canc…

This early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…

This phase 3 trial compares a combination of two experimental oral drugs, zoldonrasib and daraxonrasib, against standard chemotherapy (gemcitabine plus nab-paclitaxel) as the first treatment for people with metastatic pancreatic cancer that has a specific KRAS G12D mutation. The …

This study tests a new drug called AZD4956, alone or with other cancer drugs, in people with advanced or spreading solid tumors that have a specific DNA repair defect (HRR deficiency). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. …

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This study tests a surgery called total pancreatectomy with islet autotransplantation (TPIAT) in 30 adults with certain pancreatic tumors who are at high risk for a dangerous leak after standard surgery. The procedure removes the entire pancreas and transplants the insulin-making…

This early-phase trial tests the safety and best dose of two drugs—neratinib and trastuzumab deruxtecan—given together to people with advanced solid tumors that have HER2 gene changes. The goal is to see if the combination can shrink tumors that have spread or can't be removed by…

This early-phase study tests a new treatment for people with advanced pancreatic cancer that has spread and has a specific mutation called KRAS G12D. The treatment uses tiny particles called exosomes to deliver a molecule that blocks the mutated gene. The goal is to find the best…

This early-phase study tests an experimental drug called PF-08046876 in about 310 adults with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas that have not responded to standard treatments. The drug is a type of 'antibody drug conjugate' designed to s…

This study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…

This early-phase trial tests a new drug called PTM-101 given alongside standard chemotherapy for people with pancreatic cancer that is either borderline resectable or locally advanced (meaning it has not spread far but is hard to remove surgically). The goal is to see if adding P…

This early-phase trial is testing whether injecting the MMR vaccine directly into pancreatic tumors is safe and can help shrink them. The study will include 20 adults with borderline resectable or unresectable pancreatic cancer who have already completed standard chemotherapy and…

This study tests a drug called M3814 combined with a special type of radiation for people with locally advanced pancreatic cancer (cancer that has spread nearby but not to distant organs). The goal is to find the safest dose and see if the combination helps stop tumor growth long…

This phase 3 trial tests whether adding setidegrasib (ASP3082) to standard chemotherapy helps people with a specific KRAS G12D mutation in metastatic pancreatic cancer live longer. About 614 adults will be randomly assigned to receive either setidegrasib or a placebo, along with …

This early-stage trial tests a new drug called QXL138AM in about 100 people with advanced solid tumors (like ovarian, pancreatic, or lung cancer) or multiple myeloma. The drug is designed to help the immune system attack cancer cells. The main goal is to check safety and find the…

This early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread (metastasized). The goal is to find a safe dose and see if it can shrink tumors. The study includes adults with pancreatic, breast, or other solid tumors, and children…

This study tests a new device called DaRT that delivers a special type of radiation directly into pancreatic tumors. It is being combined with standard chemotherapy in 30 people with advanced or metastatic pancreatic cancer. The main goal is to see if the combination is safe, and…

This early-stage trial is testing whether a personalized vaccine made from a patient's own immune cells, combined with standard chemotherapy, is safe and feasible for treating pancreatic cancer after surgical removal. The vaccine is designed to train the immune system to recogniz…

This phase 2 trial is testing whether adding an experimental drug called HRS-4642 to standard immunotherapy and chemotherapy can help people with pancreatic cancer. The study includes adults with borderline resectable, locally advanced, or metastatic pancreatic cancer. Researcher…

This early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors that have high levels of a protein called mesothelin, including mesothelioma. Participants' own immune cells are collected, modified in a lab to better attack cancer, and then gi…

This phase III trial tests whether giving a higher dose of radiation can help people with locally advanced pancreatic cancer live longer. Participants must have already had 4-6 months of chemotherapy. The study compares higher-dose radiation to standard care (more chemo, observat…

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This study tests a new drug combination for people with metastatic solid tumors that lack a gene called MTAP. The drugs, BMS-986504 and pemetrexed, aim to stop cancer cells from growing. The trial will check safety and how well the combo works in 72 participants.

This study tests a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize and attack cancer cells with a specific mutation (KRAS G12V), and then infused back. Participants also receive chemotherapy and a drug to boost cell act…

This Phase 3 trial tests whether delivering chemotherapy directly into the artery feeding the tumor can help people with locally advanced pancreatic cancer live longer. Participants first get standard chemo and radiation, then are randomly assigned to either continue standard IV …

This study tests whether adding a heat-based treatment called radiofrequency ablation (RFA) to a standard procedure (ERCP) can help people with advanced pancreatic cancer that has spread to the liver live longer. About 178 adults with limited liver spread will be randomly assigne…

This early-stage study tests a new drug (177Lu-DOTA-SNA040) that delivers radiation directly to cancer cells with a specific marker (Claudin 18.2). It is for people with advanced stomach, pancreatic, or bile duct cancers that have worsened after standard treatment. The main goals…

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This phase 2 trial is testing whether combining targeted radiation therapy with two immune-boosting drugs can help people with metastatic pancreatic ductal adenocarcinoma. The study enrolls adults whose cancer has progressed after at least one line of standard treatment. Particip…

This early-phase trial tests a new drug called AB801, which blocks a protein (AXL) that helps cancers grow and resist treatment. It is given alongside chemotherapy and immunotherapy to people with bile duct or pancreatic cancer that is either borderline resectable, locally advanc…

This early-phase study tests two drugs—ulixertinib and palbociclib—together in people with advanced solid tumors, including pancreatic cancer and certain melanomas. The main goal is to find a safe dose and check for side effects. About 45 adults whose cancers have not responded t…

This early-phase trial tests whether adding pegcetacoplan to standard chemotherapy (mFOLFIRINOX) is safe and effective for people with metastatic pancreatic cancer. Pegcetacoplan targets part of the immune system to possibly slow tumor growth and reduce blood clots, a common comp…

This early-phase trial tests a drug called XER-001 (a form of amifostine given through a tube into the small intestine) combined with precise radiation therapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. The study will enroll 36 participa…

This study tests a new daily pill, GFH375, against standard chemotherapy in 320 people with advanced pancreatic cancer that has a specific KRAS G12D gene mutation. Participants must have already tried at least one standard treatment. The goal is to see if the new drug helps peopl…

This early-phase trial tests a new drug called MRG007 (ARR-217) in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check if the drug can shrink tumors. About 405 participants with colorectal, gastric, or pan…

This early-stage trial is testing an experimental vaccine called YMN-136 in people with advanced liver, pancreatic, or biliary tract cancer that has progressed after standard treatment. The main goal is to check the vaccine's safety and find the best dose, while also seeing if it…

This study tests a new treatment for adults with certain cancers (pancreatic, kidney, breast, melanoma, or ovarian) that have a protein called CD70. Doctors take a sample of your blood, modify your white blood cells in a lab to recognize and attack CD70, and then give them back t…

This study looks at whether removing the entire pancreas is better than removing just part of it for people with certain cancers in the head of the pancreas who are at high risk of complications. The main goal is to see if total removal helps patients live longer without hurting …

This early-phase study tests a combination of two drugs (BMS-986504 and olaparib) in adults with advanced solid tumors that have lost a gene called MTAP. The main goal is to find safe doses and understand side effects. About 36 people will take part, and the study is currently re…

This study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also …

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check saf…

This early-stage trial is testing an experimental drug called DM005 in 136 people with advanced solid tumors, including lung, head and neck, and other cancers that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and se…

This early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; s…

This early-stage trial tests a new drug called PHN-012 in people with advanced colon, pancreatic, or lung cancer that has stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a powerful cancer-killing agent directly to tumor cells…

This early-phase trial tests a new therapy called GC203 TIL, which uses a patient's own immune cells that are genetically modified to better attack pancreatic cancer. Ten adults whose cancer has not responded to standard treatments will receive these cells after a short course of…

This Phase 1 trial tests IDOV-Immune, a genetically engineered virus designed to infect and destroy cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatme…

This pilot trial is testing whether adding a combination of three widely used drugs—metformin, digoxin, and simvastatin (called C3)—to standard chemotherapy (gemcitabine) can safely help people with advanced pancreatic cancer that has not responded to prior treatment. The study w…

This early-stage study tests a cancer vaccine that targets a common mutated protein (KRAS) combined with two immunotherapy drugs (balstilimab and botensilimab) in people with advanced colorectal or pancreatic cancer that has spread. The goal is to see if the combination can shrin…

This study tests whether a procedure called endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) can safely treat pancreatic lesions. The approach uses a special endoscope to deliver heat energy directly to the lesion. Researchers will enroll 60 people with pre-malignan…

This early-stage trial is testing a new drug called AOH1996 in 92 adults with solid tumors (like lung, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. The drug works by blocking a protein that cancer cells need to grow. The main goals are to fi…

This study tests a new biologic drug called ANO31905 combined with standard chemotherapy as a first treatment for people with advanced pancreatic cancer that has a specific marker (CLDN18.2). The trial has two phases: first to find a safe dose, then to see if the combination shri…

This trial tests whether a virus called VCN-01, given more frequently, is safe and tolerable when combined with standard chemotherapy (nab-paclitaxel and gemcitabine) for people with newly diagnosed stage IV pancreatic cancer that has spread. Participants receive up to three dose…

This phase 3 trial tests whether a multi-disciplinary treatment plan can help people with pancreatic cancer that has spread to only a few other places in the body live longer without the disease getting worse. About 80 adults with this condition will receive either standard care …

This early-phase study tests a new oral drug called MOMA-313, alone or with another drug (olaparib), in people with advanced solid tumors that have certain DNA repair flaws. The main goals are to check safety and find the right dose. About 220 adults with cancers like prostate, p…

This early-phase trial tests a new drug called GP-2250 combined with the chemotherapy gemcitabine in people with advanced pancreatic cancer that has worsened after standard treatment. The main goal is to check safety and find the right dose. About 64 adults will take part, and re…

This early-stage study tests a new drug called PF-08046054/SGN-PDL1V, alone or with another drug (pembrolizumab), in people with advanced solid tumors like lung, head and neck, esophageal, breast, stomach, endometrial, pancreatic, or liver cancer. The main goals are to find safe …

This early-phase trial tests a new drug called TPD3310 in 112 people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive weekly injections over 28-day cycl…

This early-stage trial is testing a new chemotherapy drug called TR-002 in about 52 people with advanced solid tumors, including pancreatic cancer that has stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers wi…

This study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced or treatment-resistant solid tumors, including pancreatic cancer. The goal is to find the safest dose and see if the combination can shrink tumors. About 49 participants will take part in t…

This phase 2 trial tests a drug called zanidatamab in about 200 adults with advanced HER2-positive cancers, including breast, lung, stomach, and others. Participants have already tried at least one standard treatment. The study measures how many tumors shrink or disappear. Zanida…

This study tracks up to 30 adults who need an endoscopic ultrasound (EUS) procedure using a new device called RIVOS. The device helps doctors access and treat problems like fluid collections, blockages, or chronic pancreatitis. Researchers will measure how often the procedure wor…

This Phase 3 trial tests whether adding the targeted drug surufatinib to standard chemotherapy before surgery helps more patients with high-risk pancreatic cancer have their tumors completely removed. About 106 adults with resectable or borderline resectable pancreatic cancer wil…

This study tests a device called the HistoSonics Edison System, which uses focused sound waves (histotripsy) to mechanically break apart pancreatic tumors without surgery. The trial will enroll 50 adults with advanced pancreatic cancer that cannot be removed surgically. The main …

This study tests a new drug called IBI343, given together with standard chemotherapy pills (capecitabine) and sometimes another chemo drug (oxaliplatin), in people whose advanced pancreatic cancer has stopped responding to initial treatment. The goal is to find a safe dose and se…

This study tests a new drug, BHB810, in adults with advanced stomach or gastroesophageal junction cancer that has not responded to standard treatments. The drug is given as an IV infusion every two weeks. The main goals are to check safety and find the best dose, while also seein…

This early-phase trial is testing a new drug called PT0511, given alone or with cetuximab, in adults with advanced solid tumors that have a KRAS mutation or amplification. The main goals are to check safety, find the best dose, and see how the body handles the drug. About 195 par…

This trial tests whether a short course of focused radiation followed by chemotherapy (nab-paclitaxel and gemcitabine) plus the immunotherapy drug camrelizumab can shrink borderline or locally advanced pancreatic tumors enough to allow complete surgical removal. The study enrolls…

This study tests whether adding a targeted, tumor-destroying treatment (like focused radiation or heat ablation) can help people with certain gastrointestinal cancers—such as colorectal, small bowel, or pancreatic cancer—continue their current systemic therapy longer when only a …

This study tests whether placing a small tube (stent) in the pancreas during Whipple surgery can prevent a common complication called pancreatic fistula, where digestive fluid leaks out. The trial will compare 100 patients with a soft pancreas who either get the stent or not. The…

This early-stage trial is testing whether adding an experimental cancer vaccine (ELI-002 7P) and an immunotherapy drug (tislelizumab) to standard chemotherapy (mFOLFIRINOX) is safe and effective for people with a specific type of pancreatic cancer that has a KRAS mutation. The st…

This study tests a new approach for locally advanced pancreatic cancer: tiny radioactive sources placed directly into the tumor to deliver alpha radiation. The treatment is combined with standard chemotherapy. The main goal is to check safety in 40 participants, but researchers w…

This early-stage trial tests whether injecting an immune-boosting drug (mitazalimab) directly into the tumor during a special electrical ablation procedure (IRE) is safe for people with locally advanced pancreatic cancer. The goal is to see if this approach can strengthen the bod…

This early-stage study tests a new drug called azirkitug, alone or with other cancer medicines, in people with advanced solid tumors like lung, head/neck, and pancreatic cancers. The goal is to find safe doses and check side effects. About 694 adults will take part worldwide, rec…

This study tests a three-drug chemotherapy regimen given at lower, continuous doses for people with metastatic pancreatic cancer. The drugs—capecitabine, oxaliplatin, and irinotecan—are dosed based on a patient's genetic profile to reduce side effects. The goal is to see if this …

This early-phase trial tests an experimental drug called RSC-1255, given alone or with hydroxychloroquine, in people with advanced solid tumors (like lung, colon, or pancreatic cancer) who have run out of standard options. The study has two parts: first, finding a safe dose, and …

This trial compares two types of keyhole surgery to remove the tail of the pancreas. One uses a dye called indocyanine green that glows under special lights, helping surgeons see blood flow and decide where to cut. The other is the standard procedure without the dye. The goal is …

This study tests a combination of two drugs, pembrolizumab and olaparib, in people with advanced pancreatic cancer that has spread to other parts of the body. To join, participants must have tumors with high mutation levels or specific DNA repair problems. The goal is to see if t…

This study tests a new treatment called EGFR FPBMC for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. The treatment uses a patient's own immune cells, which are modified in the lab to better attack cancer cells, then given back through an …

This study tests a new device that delivers a special type of radiation directly into pancreatic tumors. The goal is to see if it's safe and possible to place these tiny seeds in people with advanced pancreatic cancer that can't be removed by surgery. The study will enroll 15 par…

This early-phase trial tests an experimental drug called ES502 in people with advanced pancreatic cancer that has a specific genetic change (RAS G12V) and who have run out of standard treatments. ES502 is a lab-made protein designed to guide the body's immune T-cells to attack ca…

This study tests a new device that delivers a special type of radiation directly into pancreatic tumors. It is for people with advanced pancreatic cancer that cannot be removed by surgery. The main goals are to see if the procedure is safe and possible to do. About 15 participant…

This early-phase trial is testing a new treatment called MEM-288, a virus designed to infect and kill cancer cells while also boosting the immune system. The study involves 40 adults with advanced solid tumors, including lung, skin, and breast cancers, who have not responded to s…

This early study tests a new catheter system that delivers the chemotherapy drug Gemcitabine directly into or near pancreatic tumors. It includes 9 patients with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this approach is safe and feasible…

This study tests an experimental drug called HRS-7058 in people with advanced pancreatic cancer that has a specific mutation in the KRAS gene (G12C). Participants must have already tried at least one prior treatment. The goal is to see if the drug can shrink tumors and how safe i…

This study tests a new treatment using a patient's own immune cells, called CAR T cells, that are specially designed to target and kill solid tumor cells while leaving healthy cells unharmed. It is for adults with certain advanced cancers, including lung, colon, pancreatic, ovari…

This early-phase study tests a new radioactive drug called NRT6008, given alongside standard chemotherapy, for people with advanced pancreatic cancer that cannot be removed by surgery or has spread to nearby lymph nodes. The trial will enroll 58 adults to find the safest dose and…

This study tests a new combination of drugs for people with advanced pancreatic cancer that has spread or come back. The treatment includes an experimental antibody (BMS-986340) plus immunotherapy and two chemotherapy drugs. The goal is to see if this mix is safe and shrinks tumo…

This early-phase trial is testing an experimental drug called CX-5461 (Pidnarulex) in people with advanced solid tumors (pancreatic, prostate, breast, or ovarian) that have specific BRCA2 or PALB2 gene mutations. The main goal is to find a safe and tolerable dose for future studi…

This early-phase study tests a new gene therapy for people with pancreatic cancer that has returned after standard treatment. The therapy uses a patient's own immune cells, modified to target a protein called B7-H3 on cancer cells, and includes a safety switch to control side eff…

This phase 3 trial tests whether adding radiotherapy to standard chemotherapy after pancreatic cancer surgery can prevent the cancer from coming back. It enrolls 288 high-risk patients who have had surgery but still have factors like positive margins or lymph node involvement. Pa…

This early-stage study tests a new type of cancer vaccine made from irradiated tumor and nearby cells. It aims to see if the vaccine is safe and can help the immune system fight advanced solid tumors like osteosarcoma, pancreatic cancer, and others. About 54 people will take part…

This program provides the experimental drug ulixertinib to people with advanced solid tumors that have certain gene mutations (MAPK pathway). It is for patients who have not responded well to or have run out of standard treatments. The goal is to control the disease and possibly …

This early-stage trial tests the safety of a new drug called ERX-315 in 36 adults with advanced solid tumors (like breast, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. Participants receive the drug intravenously twice a week at increasing do…

This phase 2 trial is testing whether adding the experimental drug HRS-4642 to standard chemotherapy (gemcitabine and albumin-bound paclitaxel) can help shrink pancreatic tumors before surgery and prevent recurrence afterward. About 30 adults with resectable or borderline resecta…

This phase 2 trial is testing a combination of four drugs (HRS-4642, gemcitabine, albumin-bound paclitaxel, and adebrelimab) as treatment for pancreatic cancer before and after surgery. The goal is to see if this approach is safe and effective at shrinking tumors and improving su…

This early-phase trial tests a new cell therapy called UCLH80-1 in 36 people with advanced solid tumors (colorectal, gastric, pancreatic, and bile duct cancers) that have not responded to standard treatments. The therapy uses specially engineered immune cells to target a protein …

This study tests a new drug (HRS-4642) combined with an immunotherapy (adebrelimab) and possibly other cancer drugs for people with advanced pancreatic cancer that has not responded to standard treatments. The goal is to find safe doses and see if the combination can shrink tumor…

This study tests an experimental drug called SHR-A1904 in 83 people with advanced solid tumors, including stomach and pancreatic cancers that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This study tests a new way to deliver radiation directly into pancreatic tumors using tiny radioactive beads. It is for people with locally advanced pancreatic cancer that has not spread but cannot be removed by surgery. The goal is to see if this approach is safe and feasible, a…

This study tests a type of internal radiation called high-dose-rate brachytherapy for people with liver tumors that cannot be surgically removed. The treatment uses a tiny radioactive source placed directly into the tumor to kill cancer cells while sparing nearby healthy tissue. …

This study tests whether adding a targeted drug called panitumumab to standard chemotherapy helps people with a specific type of advanced pancreatic cancer (KRAS wild-type) live longer. About 94 adults whose cancer has spread or can't be removed will be randomly assigned to get c…

This phase II trial tests whether adding a precise, high-dose form of radiation (SBRT) to standard maintenance chemotherapy can help people with advanced pancreatic cancer live longer. The study enrolls 24 adults whose cancer has not grown after at least four months of initial ch…

This early-phase trial tests a combination of three drugs—regorafenib, toripalimab, and albumin-bound paclitaxel—as a third-line treatment for people with advanced pancreatic cancer that has spread or cannot be removed. The study aims to find the safest dose and see if the combo …

This study tests a new drug called BOLD-100 combined with standard FOLFOX chemotherapy in people with advanced colorectal, pancreatic, stomach, or bile duct cancers that have spread or cannot be removed. The goal is to see if the combination is safe and helps control tumor growth…

This program offers early access to a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with serious or life-threatening cancers like colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who have tr…

This study tests a new oral drug, TNG462, combined with other treatments for people with pancreatic or non-small cell lung cancer that has lost the MTAP gene and, in some cases, has a RAS mutation. The trial has two phases: first to find the safest dose, then to see how well the …

This study tests whether adding all-trans retinoic acid to romiplostim N01 can better raise platelet counts in adults who have low platelets after finishing chemotherapy for gastrointestinal cancers. About 220 participants will receive either the combo or romiplostim alone for 12…

This study tests whether injecting gadolinium-based nanoparticles (AGuIX) before precise MR-guided radiation can improve tumor control for people with centrally located lung tumors or locally advanced pancreatic cancer. About 100 participants will receive the nanoparticle injecti…

This early-phase trial tests a new drug, UCB4594, in people with advanced solid tumors that haven't responded to standard treatments. The drug is a monoclonal antibody that targets a protein called HLA-G on cancer cells, potentially helping the immune system attack them. The stud…

This early-stage study is testing an experimental drug called MK-6204 in about 90 adults with advanced solid tumors (such as colorectal, lung, or stomach cancer) that have not responded to standard therapies. The main goals are to check the drug's safety and find the right dose. …

This early-phase trial tests adding the cholesterol-lowering drug pitavastatin to standard chemotherapy (gemcitabine and nab-paclitaxel) as maintenance therapy for people with advanced pancreatic cancer that cannot be removed by surgery. About 18 adults whose disease is stable af…

This study tests if axelopran, a drug used for opioid-induced constipation, can slow tumor growth in people with advanced breast, lung, pancreas, or prostate cancer. About 34 adults whose cancer has worsened after standard treatment will take axelopran daily for up to a year. Res…

This phase 2 trial tests a new drug called NC410 combined with standard chemotherapy (FOLFIRINOX) and immunotherapy drugs (nivolumab with or without ipilimumab) in 20 people with metastatic pancreatic cancer who have not had prior treatment. The main goal is to check safety and i…

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This study tests a new drug called ODM-212 combined with other cancer treatments in people with advanced solid tumors, including mesothelioma, pancreatic cancer, and non-small cell lung cancer. The trial has two parts: first finding a safe dose, then checking how well it works. A…

This study tests whether giving patients drugs that match their tumor's unique molecular profile can prevent pancreatic cancer from coming back after surgery. It includes 40 adults whose cancer was removed but who are at high risk of recurrence. Researchers will track how long pa…

This phase 2 trial is testing whether adding the immunotherapy drug sintilimab to chemotherapy and radiation can help people with inoperable pancreatic cancer live longer. The study will enroll 25 participants who have not had prior treatment. Researchers will track how long the …

This early-phase trial tests whether adding an experimental MK2 inhibitor (zunsemetinib) to standard chemotherapy (mFOLFIRINOX) can better control metastatic pancreatic cancer. About 51 adults who have not had prior treatment for advanced disease will participate. The main goals …

This study tests a new drug called ivonescimab, combined with targeted radiation and chemotherapy, for people with locally advanced pancreatic cancer that cannot be removed by surgery. The trial has two phases: first, finding the safest dose of ivonescimab, then checking how well…

This study tests a new drug called ZGGS34 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and second, testing how well the drug works alone or with chemotherapy in patients whose tumors have…

This study tests whether adding a low dose of erlotinib to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe and effective for people with advanced pancreatic cancer. Participants are grouped by tumor type: those with 'basal-like' tumors get the new combo, while thos…

This early-phase trial tests an experimental drug called GTB-5550 in adults with advanced solid tumors that have stopped responding to standard treatments. The drug is a nanobody designed to bridge natural killer cells to cancer cells, helping the immune system attack the tumor. …

This study tests whether giving a combination of three chemotherapy drugs (gemcitabine, cisplatin, and nab-paclitaxel) before surgery can help shrink pancreatic tumors and improve outcomes. It includes 36 adults with pancreatic cancer that is either removable or borderline remova…

This study tests a combination of chemotherapy drugs (liposomal irinotecan, 5-fluorouracil, oxaliplatin), an immunotherapy drug (adebrelimab), and radiation before surgery for people with pancreatic cancer that is either removable or borderline removable but has risk factors. The…

This study tests whether giving two different chemotherapy combinations one after the other works better than the standard single combination for people with metastatic pancreatic cancer. About 162 adults aged 18 to 75 with confirmed disease will be randomly assigned to either th…

This phase 2 trial tests whether adding two drugs (defactinib and avutometinib) to targeted radiation therapy can help people with advanced pancreatic cancer live longer without their cancer growing. About 36 participants with borderline resectable or locally advanced pancreatic …

This study tests a new drug called XNW28012 in people with advanced solid tumors (pancreatic, ovarian, cervical, or colorectal cancers) that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug shri…

This study tests a new nanovaccine made from engineered bacteria that targets KRAS mutations in colorectal and pancreatic cancer patients who have had surgery and chemotherapy but are at high risk of their cancer coming back. The vaccine is designed to train the immune system to …

This early-stage trial tests a new drug called KIVU-107 in 76 adults with advanced solid tumors that have not responded to standard treatments. KIVU-107 is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to find a safe dose and check for side…

This early-phase trial tests whether adding leflunomide, a drug used for rheumatoid arthritis, to standard chemotherapy (gemcitabine) is safe for people with advanced pancreatic cancer that cannot be removed by surgery. About 19 participants will receive the combination to find t…

This study tests a wearable device that creates electric fields (TTFields) combined with two chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that can be removed by surgery. Participants wear the device at least 18 hours daily and receive chem…

This early study tests a device called Suizenji that uses focused ultrasound waves to heat and destroy pancreatic cancer cells from outside the body. It is for 10 adults with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the treatment is safe…

This study tests a new approach for people with borderline resectable pancreatic cancer, where the tumor is close to important blood vessels but may still be removable. Participants first receive chemotherapy, then proton beam radiation combined with more chemo, followed by surge…

This study tests a short, high-dose radiation therapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. The treatment uses protons or carbon ions to deliver a precise, powerful dose in only five sessions. Researchers hope this approach will imp…

This early-stage trial is testing a new type of immune cell therapy called armored dendritic cells in 8 people with solid cancers like pancreatic or colorectal cancer. Participants have already had surgery and at least 4 rounds of chemotherapy. The goal is to see if the treatment…

This study tests a new drug, KESONOTIDE™, in people with advanced solid tumors like prostate, breast, lung, ovarian, brain, pancreas, or skin cancer. The trial has two phases: first, finding the safest dose, then testing that dose in a larger group. About 80 participants will be …

This study tests an experimental oral drug called FMC-376 in people with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific genetic change called KRAS G12C. The trial has three parts: first, finding the safest dose; then, checking how well th…

This study tests whether adding a medical glue (Glubran 2) to the surgical connection in the pancreas can prevent a serious complication called pancreatic fistula, which is a leak of digestive fluids. About 100 adults undergoing pancreas removal for cancer will be randomly assign…

This study tests a comprehensive fitness and nutrition program (prehabilitation) given before major cancer surgery. It includes 148 patients with pancreatic, ovarian, kidney, or bladder cancer who are frail or pre-frail. Some patients get the program alone, others get it with che…

This phase 2 trial is testing a daily pill called JAB-21822 (Glecirasib) in 88 people with advanced pancreatic cancer or other solid tumors that have a specific KRAS G12C mutation. Participants must have already tried standard treatments without success. The main goal is to see i…

This study tests a new drug called LM-108, given with an immunotherapy (penpulimab) and two chemotherapy drugs, in people with advanced pancreatic cancer. The goal is to see if the combination is safe and can shrink tumors or slow the disease. About 72 adults with advanced pancre…

This study tests whether a genetic test (PurIST) can help doctors choose the best chemotherapy for people with pancreatic cancer that can be surgically removed. About 84 participants will have their tumor genes analyzed from a biopsy sample, then receive a chemo plan matched to t…

This expanded access program provides DNG64-CAR-V, a gene therapy, to patients with advanced pancreatic cancer, sarcoma, or breast cancer who have exhausted standard treatments. The therapy is given intravenously or directly into tumors, alone or with other cancer drugs. Early st…

This large Phase 3 trial tests whether adding two immune-boosting drugs (ivonescimab and AK117) to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 999 participants will be randomly assigned to get the new drugs or a placebo, all with chemo.…

This study tests whether combining two drugs, AK130 and AK112, can help control advanced pancreatic cancer. About 160 adults whose cancer has worsened after up to two prior treatments will receive the combination or AK112 alone. The goal is to see if the treatment shrinks tumors …

This study tests whether adding specially designed nanocells (tiny particles that deliver a potent drug directly to cancer cells) to standard chemotherapy can help people with metastatic pancreatic cancer live longer. About 144 adults whose cancer has worsened despite prior treat…

This early study tests a new treatment called hV01, a virus modified to attack cancer cells and boost the immune system. It is for people with advanced pancreatic cancer that has not responded to standard treatments. The goal is to see if the virus can shrink tumors and control t…

This early-phase trial is testing whether adding tumor treatment fields (TTF) — a device that delivers low-intensity electric fields to disrupt cancer cell division — to a three-drug chemotherapy regimen can safely control metastatic pancreatic cancer. About 40 adults with pancre…

This study tests a new drug called CNSI-Fe(II), which is injected directly into tumors. It uses iron to trigger a type of cell death called ferroptosis, aiming to control advanced solid tumors like lung, pancreas, and colorectal cancers. The trial involves 54 adults whose current…

This early-stage study tests a new treatment called CAR-NK cells (CL-NK-003) in 9 people with advanced pancreatic cancer that has not responded to standard therapies. The main goal is to check safety and find the right dose. Researchers will also watch for signs that the treatmen…

This study tests a new treatment called EBNK-001, made from donor immune cells (natural killer cells), in people with advanced solid tumors that have not responded to standard therapies. Participants receive the cells after chemotherapy to prepare the body, along with low-dose in…

This study is testing whether adding a precise, high-dose form of radiation (SBRT) after standard chemotherapy can help control locally advanced pancreatic cancer that cannot be removed by surgery. Eighteen adults with this type of cancer will receive chemotherapy first, and if t…

This study tests a drug called pemigatinib in people with advanced or metastatic pancreatic cancer that has certain changes in the FGFR gene. The drug aims to block these abnormal genes and stop tumor growth. About 40 adults will take the pill at home and be monitored through tel…

This early-phase trial tests a combination of two immune cell therapies—dendritic cells and CAR-T cells—both engineered to target a protein called Claudin18.2 found on some pancreatic cancer cells. The goal is to see if this dual approach is safe and can shrink tumors in people w…

This trial tests an experimental drug called CP-383 in people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The drug is taken daily by mouth and works by blocking a process cancer cells need to grow. The study …

This study tests a personalized cancer vaccine (XH001) given after surgery for pancreatic cancer, followed by immunotherapy drugs (ipilimumab, sintilimab) and chemotherapy (gemcitabine + capecitabine). The goal is to see if this combination can prevent the cancer from coming back…

This Phase 3 trial is testing whether a new formulation of the chemotherapy drug paclitaxel, given with gemcitabine, works better than the current standard treatment for metastatic pancreatic cancer. The study will enroll 416 adults who have not yet received treatment for their a…

This study is for people with advanced pancreatic cancer that has spread and is no longer helped by first-line chemotherapy. It tests a mix of drugs (nal-IRI, 5-FU, leucovorin, benmelstobart, and anlotinib) with or without focused radiation (SBRT). The goal is to see if this comb…

This Phase 3 trial tests whether Kinisoquin™, a supplement-like drug made from isoquercetin plus vitamins C and B3, can prevent dangerous blood clots in 480 people with advanced pancreatic cancer. Participants receive either Kinisoquin™ or a placebo alongside their first chemothe…

This early-stage trial is testing a combination of two chemotherapy drugs (melphalan and BCNU) plus vitamins B12b and C, followed by an infusion of the patient's own stem cells. The goal is to see if this approach is safe for people with metastatic pancreatic or breast cancer, es…

This early-phase study is testing whether adding low-dose radiation and an immunotherapy drug called pucotenlimab to standard chemotherapy can help control advanced pancreatic cancer. Ten adults with pancreatic cancer who haven't had prior immunotherapy will receive the combinati…

This phase 2 trial is testing a combination of five drugs (iparomlimab, tuvonralimab, chidamide, nab-paclitaxel, and gemcitabine) as a first treatment for people with metastatic pancreatic cancer. The study aims to see if this mix can shrink tumors and improve survival. It will e…

This early-phase study tests a new treatment called PTC13, which uses specially engineered immune cells (CAR-T cells) to attack cancer cells that have a protein called CEA. The study includes 18 adults with advanced colorectal, stomach, pancreatic, or other solid tumors that have…

This study is testing an anti-PD-1 antibody (a type of immunotherapy) alone or combined with low-dose decitabine and/or standard chemotherapy in people whose cancers have come back or not responded to treatment. The trial includes patients with several cancer types, such as lymph…

This study tests a new drug called HRS-4642 combined with other cancer treatments for people with advanced pancreatic cancer that cannot be removed by surgery. About 60 adults aged 18 to 75 will take part. The goal is to see if the combination is safe and helps control the cancer…

This study tests an experimental pill called WJ22096 in about 20 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) who have run out of standard options. The goal is to find a safe dose and see if the drug can shrink tumors. Participants take the pill by m…

This study looks at how the genetic makeup of pancreatic cancer affects response to a chemotherapy called FOLFIRINOX given before surgery. About 45 adults with non-metastatic pancreatic cancer will receive the chemo, then have their tumors analyzed to see if genetic subtypes (lik…

This clinical trial is testing whether adding a device that delivers low-intensity electric fields (Tumor Treating Fields) to targeted radiation therapy can slow tumor growth in people with locally advanced pancreas cancer. Participants will receive radiation for five days and us…

This phase 2 trial tests an adaptive treatment plan for people with localized pancreatic cancer. Doctors adjust chemotherapy and radiation based on how the tumor responds, aiming to get more patients to successful surgery. The study enrolls 125 adults with resectable or borderlin…

This early-phase study tests a new treatment called IX001 TCR-T for people with advanced pancreatic cancer that has a specific genetic change (KRAS G12V). The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack the cancer. The…

This study tests new drug combinations (ADC drugs alone or with other therapies) in 160 people with advanced pancreatic cancer that has spread or cannot be removed. The goal is to find safe doses and see if tumors shrink. Participants must be 18-75, in good overall health, and ha…

This trial tests a personalized cell therapy for advanced pancreatic cancer. Patients receive their own immune cells that have been engineered to recognize and attack cancer cells with a specific mutation (KRAS G12V). The study enrolls 30 people whose tumors carry this mutation a…

This study tests whether adding donor natural killer (NK) cells to standard chemotherapy can help prevent cancer from coming back after surgery for pancreatic or bile duct cancer. About 42 adults who had their tumor removed will receive either chemotherapy alone or chemotherapy p…

This study tests whether using a person's genetic information to guide chemotherapy dosing can lower the risk of severe side effects. About 178 adults with colorectal or pancreatic cancer will be randomly assigned to either standard dosing or dosing based on their UGT1A1 gene typ…

This study tests an experimental drug called VMD-928, taken as a pill, either alone or with another cancer drug (pembrolizumab). It is for adults with advanced solid tumors or lymphoma that have not responded to or are no longer controlled by available treatments. The goal is to …

This early-phase trial is testing a treatment called tumor-infiltrating lymphocytes (TILs) in 50 people with advanced liver or pancreatic cancers that have not responded to standard treatments. Doctors take immune cells from a patient's tumor, grow them in a lab, and then infuse …

This Phase III trial is testing whether a new combination of drugs (irinotecan liposome, oxaliplatin, 5-fluorouracil, and calcium folinate) works better than the current standard treatment (nab-paclitaxel plus gemcitabine) for people with metastatic pancreatic cancer who haven't …

This study tests a combination of two immunotherapy drugs (adebrelimab and chidamide) plus two chemotherapy drugs (gemcitabine and S1) as a first treatment for people with advanced or metastatic pancreatic cancer. The goal is to see if this mix can slow tumor growth and extend su…

This study tests whether injecting a medical glue (N-butyl-2-cyanoacrylate) into the pancreas during surgery can prevent dangerous leaks. About 90 patients with pancreatic or nearby cancers will receive either standard surgery or surgery plus the glue injection. The goal is to se…

This study tests two different cancer vaccines (GVAX and a KRAS peptide vaccine) given with two immunotherapy drugs (balstilimab and AGEN2373) in people with pancreatic cancer that can be surgically removed. The goal is to find the safest dose and see if the combination helps the…

This study tests a special type of radiation called carbon ion radiotherapy in 33 frail patients with pancreatic cancer who cannot have surgery or standard chemotherapy. The goal is to see if this treatment can help them live longer and control the tumor with fewer side effects. …

This early-phase study tests whether adding a heat-based treatment (radiofrequency ablation) to chemotherapy is safe for people with advanced pancreatic cancer that hasn't spread to other organs. About 15 participants will receive the procedure through an endoscope guided by ultr…

This study tests whether a sequence of chemotherapy drugs plus two immunotherapy and anti-angiogenesis drugs works better than standard chemotherapy alone for people with advanced pancreatic cancer that cannot be removed by surgery. About 292 participants in China will be randoml…

This early-phase trial is testing a radioactive drug called 177Lu-CTR-FAPI in 4 people with advanced pancreatic cancer that has not responded to standard treatments. The drug is given intravenously every 6 weeks for up to 4 doses. Researchers are checking for safety, how much rad…

This early-phase study tests a personalized mRNA vaccine (XP-004) combined with a PD-1 inhibitor in 20 patients who cannot tolerate chemotherapy after pancreatic cancer surgery. The goal is to see if the treatment is safe and can train the immune system to fight remaining cancer …

This master trial is testing a new radiation technique called SMART, which uses MRI to guide and adapt radiation beams in real time. The goal is to deliver high doses precisely to tumors while protecting nearby organs. The study enrolls adults with various cancers (pancreas, lung…

This early-stage trial tests a procedure called irreversible electroporation (IRE), which uses electric pulses to destroy tumor cells, combined with standard chemotherapy drugs (gemcitabine or FOLFIRINOX). The study includes 20 adults with stage III pancreatic cancer that hasn't …

This early-phase trial tests whether a patient's own white blood cells, loaded with a chemotherapy drug, can safely treat unresectable pancreatic cancer. Only 3 people will take part. The main goal is to check for side effects, not to cure the disease.

This program provides early access to an experimental drug called AVM0703 for people with various solid tumors and blood cancers, including hard-to-treat types like glioblastoma and metastatic breast cancer. It is available to patients in the US whose doctor requests it. So far, …

This early-stage study is testing a new treatment called CEA-targeted CAR-T cells for people with advanced solid tumors like lung, stomach, colon, rectal, esophageal, or pancreatic cancer that have not responded to standard therapies. The treatment uses a patient's own immune cel…

This study tests whether giving chemotherapy and radiation before surgery can help surgeons remove all of the pancreatic cancer. About 30 adults with resectable pancreatic cancer will receive the drugs gemcitabine and nab-paclitaxel plus targeted radiation, then surgery, then mor…

This Phase 3 trial is testing whether adding an experimental drug called QLS31905 to standard chemotherapy helps people with advanced pancreatic cancer live longer. The study includes 602 adults whose tumors have a specific marker (CLDN18.2). Participants are randomly assigned to…

This phase II study tests a new drug called IBI343, which targets a protein on cancer cells, combined with standard chemotherapy (gemcitabine and albumin-bound paclitaxel) in 64 people with advanced pancreatic cancer. The trial has two parts: a safety lead-in and a randomized ext…

This phase 3 trial tests whether adding a surgical glue called N-butyl-2-cyanoacrylate to standard pancreatic surgery can prevent postoperative pancreatic fistula—a common and serious leak of digestive fluids. About 194 patients with soft pancreas tissue undergoing tumor removal …

This early-phase study tests a new drug called BL-M17D1 in 20 people with advanced HER2-positive gastrointestinal cancers (like stomach, pancreas, or colon cancer) or other solid tumors. The main goals are to check safety, find the right dose, and get a first look at whether the …

This phase 2 trial tests whether a higher dose of proton radiation combined with the oral chemotherapy drug capecitabine can help people with unresectable pancreatic cancer live longer and possibly become candidates for surgery. The study enrolls 60 patients whose tumors cannot b…

This study tests whether a special nutritional formula (Peptamen 1.6) helps malnourished pancreatic cancer patients recover better after a major surgery called pancreaticoduodenectomy. Twenty adults who are malnourished or at risk will receive two different nutritional drinks in …

This study explores whether a common blood test that measures how well blood clots (called TEG) can also act as a biomarker for cancer. Researchers will compare TEG results from patients with several types of cancer (liver, pancreas, bile duct, esophagus, colorectal, and lung) ag…

This study tests a new technology called NEO-Match® that measures the stiffness of pancreatic tissue from a biopsy sample. Researchers want to see if this test can predict how well a patient will respond to cancer treatment and help diagnose pancreatic cancer more accurately. Abo…

This trial is testing whether a new radioactive tracer, called 68Ga-SorB, can help doctors see certain solid tumors on PET/CT scans. The tracer targets sortilin, a protein that is often found on cancer cells. About 50 adults with melanoma, liver, lung, breast, pancreatic, or ovar…

This study tests a special PET scan that uses a radioactive tracer called 68Ga-FAPI-46 to highlight pancreatic cancer cells. The goal is to see if this scan can find tumors more accurately than current methods. About 130 adults with early-stage pancreatic cancer will get the scan…

This study is testing whether a new MRI technique using a substance called hyperpolarized pyruvate gives consistent results in people with solid tumors. About 109 participants will have two special MRI scans to see if the images are reproducible. The goal is to improve how doctor…

This study is testing a new blood test called PANXEON that looks for tiny genetic particles (miRNAs) to detect pancreatic cancer early. Researchers will collect blood samples from 2,000 people—some with pancreatic cancer and some without—to see how accurate the test is. If it wor…

This study tests a radioactive compound called IR199 in people with gastric or pancreatic cancer that has a specific marker, Claudin 18.2. The goal is to see how the compound spreads through the body and how much radiation reaches tumors and healthy organs. Ten participants recei…

This study is testing a new blood test that looks at tiny particles called exosomes and their microRNA content, analyzed by machine learning, to detect pancreatic cancer early. It involves 600 people at high risk due to family history or pancreatic cysts. The goal is to see if th…

This study is testing a non-invasive breath test to detect pancreatic cancer earlier. Researchers will collect breath samples from over 6,000 people who have been referred for possible pancreatic cancer. The goal is to see if the test can accurately identify the small number of p…

This study tests a dedicated MRI scan of the pancreas (MRP) to see if it can detect pancreatic cancer earlier in people at high risk. About 79 participants with a strong family history or certain genetic mutations will get both the new MRI and an endoscopic ultrasound. The goal i…

This study is testing a new blood test called EXoPred that uses artificial intelligence and laser technology to find tiny particles from cancer cells. The goal is to detect breast, colon, pancreatic, ovarian, and lung cancers at an early stage. Researchers will enroll 1,400 peopl…

This study is testing a new blood test called Enzeavour that looks for tiny signs of pancreatic cancer in healthy people. About 10,000 adults in Japan getting routine checkups will give a blood sample. If the test shows a high score, they will get further imaging to check for can…

This study looks for early signs of pancreatic cancer in fluid from pancreatic cysts. Researchers will measure specific molecules in the fluid to see if they can accurately tell which cysts are cancerous. The goal is to develop a less invasive test than current methods, helping c…

This study is testing a blood test that looks for tiny bits of cancer DNA (ctDNA) in people with esophageal, gastric, or pancreatic cancer. The goal is to see if it can find signs of cancer coming back or getting worse earlier than current methods. About 34 participants will give…

This study compares two blood test methods for detecting circulating tumor cells (CTCs) that express a protein called Axl, which is linked to more aggressive cancer. The new technique, called EPIDROP, is being tested against the standard CellSearch method in patients with metasta…

This study tests a new type of PET/CT scan (using [68Ga]Ga-FAPI-46) to see if it can find and stage gastroesophageal and pancreatic cancers better than current scans. About 90 adults with these cancers will get the new scan before surgery or treatment, and some will have a second…

This study tests a dye called CYTALUX (pafolacianine) that attaches to cancer cells and glows under a special camera during surgery. About 50 adults with certain cancers (like esophageal, pancreatic, or gynecologic) will get the dye before surgery. The goal is to see if the glowi…

This study aims to see if adding simple blood tests and symptom reviews to standard screening can catch pancreatic cancer earlier in people with a high genetic risk. Researchers will enroll 5,000 participants who have certain gene mutations linked to pancreatic cancer. The goal i…

This study is testing a new scoring system called OC26 to help doctors more accurately diagnose autoimmune pancreatitis, a condition where the immune system attacks the pancreas. Researchers will review medical data from 82 adults suspected of having the disease. If the OC26 crit…

This study tests a new radioactive imaging agent that targets a protein called MSLN, found on some cancer cells. Researchers will use PET scans to see if this agent can better detect and stage ovarian cancer, lung adenocarcinoma, and pancreatic cancer in 100 patients and healthy …

This early-stage study is testing a new contrast agent called 68Ga-NODAGA-SNA014, which targets a protein (CLDN18.2) found on some pancreatic cancer cells. The agent is used with PET/CT scans to see if it can safely and accurately highlight tumors. The study involves 12 adults wi…

This study aims to develop a non-invasive breath test to detect pancreatic cancer earlier. Pancreatic cancer is often diagnosed late because early symptoms are vague. The test measures tiny molecules in breath that may signal cancer. Researchers will collect breath and urine samp…

This study is testing a new imaging agent called 18F-T2, which is designed to highlight tumors that produce a protein called CAIX. About 200 adults with various cancers (like kidney, lung, or breast cancer) will receive an injection of 18F-T2 and then undergo a PET/CT scan. The g…

This study is testing a software called Lipidica that analyzes fats in the blood to help screen for pancreatic cancer. Researchers will compare results from people with pancreatic cancer to those at high risk (due to family history or genetic factors) to see if the software can t…

This study is testing a new radioactive imaging agent that targets a protein called LRRC15, found on many cancer cells. Researchers will use PET scans to see if this agent can better detect and stage cancers like pancreatic, breast, lung, and others. The trial includes 26 healthy…

This study is testing whether adding an MRI scan to the usual CT scan helps doctors make better decisions about surgery for pancreatic cancer. About 200 patients who are initially thought to be candidates for surgery will be randomly assigned to get either a standard CT alone or …

This study is testing whether regular screening with endoscopic ultrasound (EUS) or MRI can find early signs of pancreatic cancer in people at high risk. About 1,395 participants will be screened, and researchers will track how many have high-risk lesions that can be treated. The…

This study is screening 200 people with a strong family history or genetic mutations linked to pancreatic cancer. Participants get an annual MRI/MRCP scan to look for early-stage cancer or pre-cancerous growths. They also donate blood samples to help develop a future blood test f…

This early-stage trial is testing a new radioactive tracer called 68Ga-FXX489 (NNS309) for PET/CT scans. The goal is to see if it can safely and accurately detect tumors and their spread in 30 adults with suspected cancer. Researchers will measure how the tracer moves through the…

This study explores whether a magnetic resonance spectroscopy (MRS) scan of the thigh can predict a patient's fitness for major cancer surgery, as an alternative to the standard cardiopulmonary exercise test (CPET). Researchers will compare fat levels in thigh muscles from the MR…

This study looks at whether the things people buy at stores—like pain relievers or digestive aids—could be early warning signs of cancer. Researchers will compare the shopping habits of 2900 people, some diagnosed with cancer and some not, to see if certain purchases happen more …

This study is testing a new blood test called Avantect to see if it can find pancreatic cancer early in people who were diagnosed with type 2 diabetes in the last 6 months. About 15,000 adults aged 50-84 will give blood samples and fill out anxiety questionnaires over a year. The…

This study tests an artificial intelligence (AI) system that analyzes contrast-enhanced CT scans to help diagnose and manage pancreatic diseases. The AI will classify patients into three groups: needing immediate treatment, close monitoring, or routine follow-up. Researchers will…

This study tests a small, portable device called P4 that sits inside an MRI scanner to improve the accuracy of scans for pancreatic cancer. Researchers want to see if it can reduce errors when measuring blood flow in tumors, which helps doctors know if treatment is working. The t…

This study tests a special PET probe called [68Ga]CBP8 to see if it can detect tissue damage caused by radiation therapy in people with lung or pancreatic cancer. About 72 participants will get a PET scan before and 3-6 months after radiation. The goal is to find early signs of r…

This study is testing a new platform that uses advanced testing to get a complete picture of a person's tumor. The goal is to see if this detailed information can help doctors choose better treatments for patients with high-risk cancers like leukemia, multiple myeloma, and pancre…

This study is testing a new way to detect cancer by looking at certain enzymes in the blood. Researchers will collect blood samples from 220 people—120 with breast, lung, or pancreatic cancer and 100 without cancer. They want to see if the enzyme levels are different between the …

This study is testing a blood test that looks for DNA signals from 20 different cancers, including lung, breast, and colon cancer. Researchers will see if the test can find cancer early, detect any cancer left after treatment, and catch a relapse before it shows up on scans. The …

This study tests a new type of PET scan that uses a special tracer to light up a protein called FAP, found on pancreatic tumor tissue. The goal is to see if this scan can detect cancer spread that standard CT scans miss. Researchers will compare the new scan with CT in 60 adults …

This study tests a special dye and imaging system to help surgeons see colorectal, pancreatic, esophageal, and stomach cancers during surgery. About 66 adults scheduled for cancer surgery will receive the dye, and the imaging system will check if it lights up cancer tissue. The g…

This study is testing a new AI-powered blood test that looks at platelets and immune cells to find early signs of eight different cancers, including lung, breast, and pancreatic cancer. Researchers will collect blood samples from 6,000 adults aged 40 and older, both with and with…

This study is testing a new type of PET scan that uses special probes to highlight digestive system cancers, such as stomach, liver, colon, and pancreatic cancers. Researchers will enroll 400 adults to see how well this imaging method finds tumors and tracks their response to tre…

This study tests three new radioactive imaging probes that attach to proteins found on pancreatic cancer cells. By using PET/CT scans, doctors hope to see where the cancer has spread and predict which patients might respond to targeted drugs. The trial will enroll 90 adults with …

This study tests a new PET imaging probe that targets a protein called CLDN18.2, found in some stomach, pancreatic, bile duct, and esophageal cancers. Researchers will scan 56 people (patients and healthy volunteers) to see if the scan can accurately detect tumors and guide treat…

This Phase 3 study is testing whether markers in pancreatic fluid and blood can detect early pancreas cancer in people with high genetic risk. Participants receive a secretin injection to collect fluid during an endoscopy. The goal is to improve early detection in those with here…

This study tests whether a smartphone app, combined with nutrition education, can help people at high risk for cancer eat healthier and reduce their cancer risk. About 170 participants will either get the app or standard advice, and researchers will measure changes in diet qualit…

This study tests if giving the drug lanreotide before pancreatic surgery can prevent a common complication called a pancreatic fistula, which is a leak of digestive fluids. About 274 people with pancreatic cancer or precancerous lesions will be randomly assigned to receive either…

This study tests whether a personalized exercise program, tracked by a smartwatch, can help reduce fatigue in people who have finished chemotherapy for certain cancers (breast, colorectal, ovarian, pancreatic, or gastric). About 98 participants will be randomly assigned to either…

This study tests whether a remote exercise and nutrition program is practical and acceptable for people with pancreatic cancer who are waiting for surgery. Participants will use a Fitbit, get nutrition advice, and do resistance training at home. The goal is to see if this 'prehab…

This phase II trial tests whether a standardized acupuncture protocol can reduce peripheral neuropathy, a common and often lasting side effect of oxaliplatin chemotherapy. Participants are adults with gastrointestinal solid tumors who stopped oxaliplatin-based treatment and still…

This study compares two types of nerve blocks—coeliac plexus block and splanchnic nerve block—to see which one reduces pain better in adults with upper abdominal cancer. Forty-four participants will receive one of the procedures and be monitored for pain, opioid use, and quality …

This trial tests a supportive web-based app for people with advanced pancreatic, biliary tract, or non-small cell lung cancer who are about to start their first line of chemotherapy. Each week, participants answer questions about their symptoms using the app. If their answers sug…

This study compares a new radiation technique called lattice radiation therapy (LRT) to standard stereotactic body radiation therapy (SBRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better and helps the immune system f…

This study is testing a new web-based program designed to help people with pancreatic cancer manage stress and symptoms. Sixty participants will complete weekly one-hour online sessions for ten weeks, learning relaxation, coping, and communication skills. The goal is to see if th…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This pilot study tests whether a new, faster radiation planning method can safely ease severe abdominal pain caused by advanced cancer. Instead of a separate planning session, doctors use existing scans to create a treatment plan on the spot. Only 5 people will take part, and the…

This phase 3 trial tests whether a combination of ear acupressure (stimulating specific points on the ear) and a low dose of the steroid dexamethasone can prevent nausea and vomiting from chemotherapy as effectively as standard antiemetic drugs in pancreatic cancer patients. Part…

This study tests a quicker method of giving radiation therapy to ease severe abdominal pain caused by pancreatic cancer. Normally, preparing for this treatment takes a week or more because a special planning CT scan is needed. Here, doctors will use the patient's existing diagnos…

This study tests whether riluzole, a drug already used for ALS, can help cancer survivors who struggle with memory, focus, and mental clarity after treatment — a condition called cancer-related cognitive impairment. Researchers will measure changes in a brain protein called BDNF …

This pilot study tests whether a 36-session targeted exercise program can help frail pancreatic cancer patients stay stronger and complete their chemotherapy with fewer problems. Researchers will enroll 25 patients who are frail or pre-frail and receiving chemotherapy before surg…

This trial tests a web-based program called COMPASS that provides personalized exercise and nutrition advice, along with text messages, activity trackers, and coaching, for people with stage I-III pancreatic cancer receiving chemotherapy before surgery. The goal is to see if the …

This study tests whether taking omega-3 fish oil capsules and doing simple resistance exercises with elastic bands can help cancer patients maintain muscle mass and strength. It involves 288 adults with various cancers who are at risk of muscle wasting. The goal is to improve phy…

This early-stage trial tests a new drug called GB18 in 18-36 cancer patients who are losing weight and appetite due to their illness (cachexia). The drug is given as a shot under the skin. The main goal is to check safety, but researchers will also see if it helps patients gain w…

This study tests whether adding acupuncture and acupressure to standard anti-nausea medicine can better reduce chemotherapy-induced nausea. About 90 cancer patients with ongoing nausea will be split into two groups: one gets the extra acupuncture, the other gets medicine alone. T…

This study tests a new drug called JMT203 in people with lung, pancreatic, or colorectal cancer who are experiencing cachexia (severe weight loss and muscle wasting). The drug is an antibody that targets a protein linked to appetite loss. The trial will enroll about 307 participa…

This study tests whether a high-protein nutrition plan combined with resistance exercises, started weeks before surgery and continued for 24 weeks after, can help older adults with cancer preserve their physical function. The trial enrolls Veterans aged 55 and older with certain …

This study tests whether a community health worker can help people newly diagnosed with pancreatic cancer feel better and manage their symptoms. The health worker meets with patients and their caregivers to address physical, emotional, and practical concerns, and helps coordinate…

This pilot study tests whether brodalumab, a drug used for autoimmune conditions like psoriasis, can safely reduce immune-related side effects caused by cancer immunotherapy. About 11 adults with advanced solid tumors who developed these side effects will receive brodalumab injec…

This study tests whether giving a nerve block early, rather than waiting, can better control pain in people with inoperable pancreatic cancer. The procedure uses an endoscope to inject numbing medication near nerves that carry pain signals. Researchers will compare pain scores an…

This study looks at a procedure called EUS-guided celiac plexus neurolysis (EUS-CPN) to help manage pain from pancreatic cancer. Doctors usually inject a numbing drug (bupivacaine) before alcohol to prevent pain, but it's unclear if it helps or might even reduce the procedure's e…

This study tests whether combining ear acupressure (using small seeds on specific ear points) with the steroid dexamethasone can better prevent or reduce nausea and vomiting caused by chemotherapy in pancreatic cancer patients. About 25 participants will receive the treatment bef…

This pilot study is testing whether a structured program of exercise, nutrition counseling, and support—called prehabilitation—can help adults with pancreatic cancer get stronger before surgery. Twenty participants will follow the program while receiving chemotherapy before their…

This study compares two minimally invasive nerve block techniques to relieve severe upper abdominal cancer pain that hasn't responded to standard treatments. About 56 adults with stomach, pancreatic, or liver cancer will receive either a transdiscal or paravertebral approach. The…

This study tests whether using virtual reality (VR) can reduce severe belly pain and improve quality of life in people with digestive tract cancers. 360 participants will be split into three groups: one using a skills-based VR program, one using distracting VR videos, and a contr…

This study looks at whether a home-based resistance exercise program combined with protein supplements can help people with pancreatic cancer maintain muscle mass while on chemotherapy. About 45 participants will be assigned to one of three groups: exercise plus protein, exercise…

This study tests whether adding psychosocial (emotional) support to standard prehabilitation helps patients with localized pancreatic cancer during neoadjuvant therapy (chemotherapy/radiation before surgery). Sixty adults will receive nutritional advice, physical therapy, and psy…

This study is for people with advanced bile duct or pancreatic cancer who have significant pain. Researchers want to see if adding a nerve-blocking pain treatment (celiac plexus block) to standard first-line cancer therapy helps control pain and shrink tumors better than standard…

This study compares three routine pain control methods used during minimally invasive cancer surgery: a nerve block plus local anesthetic, nerve block alone, or local anesthetic alone. About 48 adults having surgery for various cancers will be randomly assigned to one of the thre…

Researchers are studying whether a next-generation radiation delivery system can run a complete treatment workflow while patients hold their breath. The trial enrolls about 20 adults with tumors in the chest or upper abdomen who are already scheduled for stereotactic body radiati…

This study is for people with pancreatic cysts or other pancreas issues. Researchers will collect blood, tissue, and scan data from over 1,100 participants to create a large database. The goal is to develop noninvasive tools that predict which cysts may become cancerous, helping …

This study is developing and testing a mobile app designed to help Black people with pancreatic cancer learn about and discuss clinical trials with their doctors. The goal is to increase their participation in these trials, which is currently much lower than for White patients. R…

This study is for Black adults newly diagnosed with gastrointestinal cancer. It focuses on ensuring patients receive proper biomarker testing and evidence-based care, helping them find and join clinical trials if they choose, and providing easy-to-understand information about the…

This study looks at whether it is safe to skip placing a drain in the belly after surgery to remove part of the pancreas. About 234 adults having this surgery will be randomly assigned to get a drain or not. The goal is to see if not using a drain leads to fewer serious problems …

This study looks at genetic changes in metastatic pancreatic cancer to see if they can help guide treatment choices. Researchers will take tumor biopsies and blood samples from 190 patients starting chemotherapy. The main goal is to see if genetic test results can be returned wit…

This study looks at whether adding a geriatrician (a doctor who specializes in care for older adults) to cancer treatment can improve outcomes for people aged 70 and older with gastrointestinal cancers like stomach, colon, or pancreatic cancer. Researchers will test if an online …

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

Researchers at IRCCS San Raffaele are creating a registry of images and videos from endoscopic ultrasound procedures performed to investigate pancreatic diseases. The study will gather data from about 12,000 patients with conditions like pancreatitis, pancreatic cancer, and neuro…

This observational study in Vietnam looks at archived tumor samples from patients with several solid cancers, including liver, colorectal, gastric, breast, lung, endometrial, melanoma, and pancreatic cancer. Researchers will measure the presence of two proteins, ENPP1/cGAS and FA…

This early phase trial is testing several targeted drugs in people with pancreatic cancer to see how they affect tumor biology. Researchers will compare tumor samples taken before and after treatment to understand which drugs might work best. The goal is not to treat the cancer d…

This observational study follows 8,000 people with pancreatic cancer to map their real-world diagnostic and treatment journeys. Researchers will track overall survival and look for factors that influence treatment decisions and outcomes, including patient-reported experiences. Th…

This observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…

This study aims to find pancreatic cancer earlier in people who are at higher-than-average risk due to family history or genetic mutations. Researchers will collect blood samples and health data from 30,000 participants over time to build a biobank. The goal is to improve early d…

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This registry is collecting information from 1,500 people with advanced pancreatic cancer in Austria to see how different chemotherapy treatments work in everyday practice. Researchers will track which treatments are used, how well they work, and what side effects occur. The goal…

This pilot study compares two ways of collecting blood to detect circulating tumor DNA (ctDNA) in people with liver or pancreatic cancers. Researchers will take blood from a standard arm vein and also from the vein that drains directly from the tumor during a biopsy. The goal is …

This study is looking at why some people with advanced cancer lose weight and muscle, a condition called cachexia. Researchers will follow 800 patients with advanced lung, pancreatic, or colorectal cancer to see if there are distinct subtypes of cachexia based on symptoms, biomar…

This study is for people with cervical or pancreatic cancer who are scheduled to receive chemoradiotherapy. Researchers will collect tumor samples, blood, and imaging data before, during, and after treatment to see how the tumor environment changes over time. The goal is to learn…

This study aims to create a simple, minimally invasive test to find pancreatic cancer at an early stage and track how well treatment is working. Researchers will study 700 people with pancreatic cancer, pancreatitis, or pancreatic cysts. The goal is to identify biological markers…

This study is a large registry that collects health and genetic information from people with a personal or family history of pancreatic tumors. The goal is to find the genes and other factors that cause pancreatic cancer to run in some families. By studying thousands of participa…

This study is checking if the diabetes medicine exenatide (Byetta, Bydureon) increases the risk of pancreatic cancer. Researchers will look at health records from 24,000 patients across seven European countries, comparing those who started exenatide with those who started other d…

This study is tracking 20,000 people who have a family history of pancreatic cancer or carry genes that raise their risk. Researchers hope to find better ways to detect the disease early, when it's more treatable. Participants will be followed over time to see who develops pancre…

This study aims to create and improve educational materials about genetic testing for cancer patients from diverse backgrounds. Researchers will interview 445 people with breast, ovarian, pancreatic, prostate, or colorectal cancer who speak English, Spanish, or Haitian Creole. Th…

This study looks at whether CT scans can help doctors predict how well chemotherapy will work for people with pancreatic or liver cancer. About 259 adults with these cancers will get CT scans before and during treatment. The goal is to see if changes in the scan can tell if the t…

This study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…

This study looks at the energy needs of people who have surgery to remove part or all of the pancreas for a tumor. After such surgery, patients often have trouble eating enough and may need special nutrition. The study measures how many calories patients actually burn and compare…

This observational study looks at whether combining CT scans, blood tests, and pathology reports can more accurately predict how pancreatic cancer will progress. Researchers will collect existing medical records from about 1,030 participants who had surgery for pancreatic cancer.…

This study looks at 100 people who have had a Whipple procedure (pancreaticoduodenectomy) for cancers of the pancreas or nearby areas. The goal is to find factors before, during, and after surgery that raise the risk of a pancreatic fistula—a leak of digestive fluid that can caus…

This study looks at how ongoing stress, anxiety, and poor sleep might affect the course of pancreatic cancer. Researchers will ask 320 participants to fill out simple questionnaires about their mental well-being and will also measure stress markers in leftover blood samples. The …

This study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…

This study looks at why people with pancreatic cancer often lose muscle and weight (cachexia). Researchers will collect blood, tissue, and imaging data from 500 patients to understand the biology and build an AI model that could warn doctors early. It is an observational study, s…

This study tests a digital app called the Genetics Adviser for Mainstream Care (GA-Mainstream) that educates cancer patients about genetic testing and delivers their results. Researchers want to see if using the app reduces distress and improves the patient experience compared to…

This study aims to discover new genes that may cause certain cancers to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had cancer, especially childhood cancers. The goal is to build a regist…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can help predict how well pancreatic cancer patients respond to chemotherapy. Researchers will track ctDNA levels before, during, and after treatment in 500 patients whose cancer has not spread. The goal …

This trial investigates whether a lidocaine infusion given during pancreatic cancer surgery can affect circulating tumor cells (CTCs) — cancer cells that may travel through the blood. Researchers will compare lidocaine to a saline placebo in patients undergoing robotic pancreatec…

This study investigates whether the unique bacteria found inside digestive system tumors can help predict how well a patient will respond to neoadjuvant therapy (chemotherapy before surgery). Researchers will analyze tumor samples from 90 adults with pancreatic, gastric, colorect…

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This study looks at ways to increase genetic testing for people with breast, pancreatic, or colorectal cancer. Researchers will try different methods—like training doctors, giving feedback, and improving electronic health records—to see what helps oncology teams order more tests.…

This study explores whether a special MRI technique called 3D-MRE can measure the stiffness of pancreatic tumors to help predict how the disease will progress. Researchers will enroll 200 adults with pancreatic cancer and compare imaging results with actual tumor hardness and tre…

This study is a registry that will follow 50 adults who are already scheduled to receive EUS-guided radiofrequency or microwave ablation for pancreatic or other gastrointestinal lesions as part of their routine care. Researchers will collect data from medical records to see how t…

This study uses a special microscope called intravital microscopy to look at blood vessels inside solid tumors while patients are in surgery. Researchers want to see how these vessels work and how well they let blood and dye flow through. The goal is to learn whether tumor vessel…

This study is creating a large database of 1,000 people with KRAS-mutant pancreatic cancer who are receiving targeted therapy. Researchers will track how long patients live and how long their cancer stays under control. The goal is to learn which treatments work best for differen…

This study looks at how obesity might help cause pancreatic cancer, especially in African American and non-Hispanic White people. Researchers will compare tumors and fat tissue from 125 adults to find differences that could lead to better treatments. The goal is to understand why…

This study is testing whether an 8-minute educational video can effectively prepare cancer patients for genetic testing, compared to standard genetic counseling. Over 1,000 adults with various cancers will participate. The goal is to see if the video is acceptable and improves un…

This study is developing an AI system that tracks tumors and organs during radiation therapy without needing physical markers. Researchers will use existing patient data to train and test the AI. If it works, it could help doctors target radiation more accurately. The study invol…

Cancer patients face a higher risk of blood clots during chemotherapy, but it's hard to know who is most at risk. This study will measure clotting-related biomarkers in the blood of 380 patients with ovarian, lung, stomach, or pancreatic cancer at four points during their treatme…

This study looks at medical records from 1,000 adults with pancreatic cancer to see if treatments chosen based on each tumor's genetic profile lead to better results. Researchers will track how many patients receive a genetically matched therapy and how well they respond. The goa…

This study is testing a software tool that uses DNA from a blood sample to predict the risk of blood clots returning in people with cancer who have finished 3-12 months of blood thinner treatment. The goal is to see if a low-risk result means it's safe to stop blood thinners with…

This study looks for three common BRCA gene mutations in 100 Ashkenazi Jewish people with pancreatic cancer. By understanding how often these mutations occur, researchers hope to improve early screening and prevention for at-risk family members. Participants provide a sample and …

This study tests whether personalized nutrition plans can improve recovery after Whipple surgery for pancreatic, bile duct, or ampullary cancers. Twenty patients in Pakistan will receive tailored meals and supplements before and after surgery, and be followed for 6 months. Resear…

This study collects blood, urine, and bone marrow samples from 620 people with solid cancers like lung, colorectal, and pancreatic cancer. Researchers will look for tumor cells and DNA in these samples to understand how cancer spreads and why it sometimes comes back after surgery…

This study is collecting tissue and fluid samples from 160 people with suspected liver, bile duct, or pancreatic cancers. Researchers want to understand these cancers better and test new imaging and sampling tools for earlier, more accurate diagnosis. The study does not test a ne…

This observational study is analyzing tumor and blood samples from 50 people with pancreatic cancer to measure levels of certain proteins called convertases. Researchers want to see if these protein levels are linked to immune cells in the tumor, which could help predict how the …

This study looks at tiny molecules called microRNA in the blood of people with advanced pancreatic cancer. Researchers want to see if these molecules can help diagnose the disease earlier, predict how it will progress, and show whether treatment is working. The study will follow …

This study looks at whether people aged 50+ who are newly diagnosed with diabetes (or whose diabetes gets worse) might have early-stage pancreatic cancer. Researchers will use MRI scans and collect blood samples over time to find cancer or pre-cancerous changes. The goal is to de…

This study is creating a repository of tumor, tissue, and blood samples from cancer patients. The goal is to store these biospecimens for future research that could improve our understanding of cancer. Up to 10,000 participants will provide samples during their routine care at th…

This study collects blood samples from 30 adults with pancreatic cancer to build a library for future research. The goal is to store specimens and health data together, creating a powerful tool for scientists to study the disease. Participants must be patients at the University o…

The PREDICT study is creating a registry and biospecimen bank for people with pancreatic disease or at high risk for pancreatic cancer. Researchers will collect blood, tissue, urine, and other samples from 1,000 participants to study the causes and biology of the disease. This is…

This study looks at the genes of 750 people with advanced or metastatic pancreatic cancer. The goal is to find specific genetic changes that could help doctors choose better treatments, like targeted drugs or chemotherapy combinations. Participants must have a tumor sample availa…

This study looks at whether a simple blood test can find tiny bits of tumor DNA (ctDNA and eccDNA) in people with pancreatic cancer that can be surgically removed. The goal is to see if these tests can predict if the cancer will come back early and help doctors monitor patients m…

This early phase 1 trial is studying how the drug OMO-103 affects pancreatic cancer cells in 12 patients with advanced or metastatic pancreatic ductal adenocarcinoma. The main goal is to see if the drug changes the tumor's biology by analyzing tissue samples before and after trea…

This study is testing whether a simple rectal mucus sample can detect DNA changes linked to lung, pancreatic, bladder, and colorectal cancers. Researchers will collect samples from 450 adults using a special device and analyze them for genetic and epigenetic markers. The goal is …

This study collects blood, tissue, and health information from 20,000 people with pancreas diseases like pancreatic cancer, pancreatitis, or cysts. The goal is to create a large database and sample bank that researchers can use to better understand these conditions and develop be…

This study enrolls 5,000 people at high risk for pancreatic cancer to donate blood, pancreatic juice, and medical images over 10 years. Researchers will use this information to develop and validate tests that can detect pancreatic cancer earlier, when it may be more treatable. Pa…

This pilot study tests a tiny implantable device that delivers microdoses of several chemotherapy drugs directly into pancreatic tumors during surgery. The device is removed after four hours, and the surrounding tissue is analyzed to see which drugs worked best. Ten adults with p…

This study is a large registry that will follow about 8,000 cancer patients who receive radiation therapy using a special machine called an MR-Linac, which combines an MRI scanner with a radiation beam. The goal is to learn how well this technology works for different cancers, in…

This study collects tissue, blood, urine, and stool samples from 5000 people undergoing colonoscopy or endoscopy, including those with cancer, polyps, or inflammatory bowel disease, as well as healthy volunteers. The goal is to find new biomarkers that could improve early detecti…

This study is looking at tiny pieces of tumor DNA (ctDNA) in the blood of 50 people with pancreatic cancer that can be surgically removed. Researchers want to see how often ctDNA is found and whether it relates to how long patients live without the cancer getting worse. The goal …

This study looks at how well patients understand the information they get before major abdominal cancer surgery and whether that affects regret afterward. Researchers will survey 90 adults before surgery, then one month and three months after. The goal is to improve how doctors c…

This study follows 5,000 adults with pancreatic cysts to understand how these cysts behave over time. Researchers aim to create a better way to tell which cysts are harmless and which may turn into cancer. Participants provide medical records and samples, but no new treatment is …

This study tests whether a special MRI technique called DCE-MRI can guide chemotherapy for people with borderline resectable pancreatic cancer. The goal is to see if this imaging method can better track tumor blood flow and help doctors decide if the treatment is working, so they…

This study is testing whether a monthly blood test can predict dangerous blood clots in people with certain cancers (lung, pancreatic, stomach, or brain). Cancer patients are at high risk for clots, which can be deadly. Researchers will follow 200 participants for 12 months, taki…

This study creates a registry of people with pancreatic diseases or a high risk for pancreatic cancer, such as those with a family history or certain genetic mutations. Researchers will collect medical information and blood samples to study how these conditions develop over time.…

This study looks at tiny particles called exosomes, which carry proteins and genetic material between cells. Researchers will collect blood and tissue from 181 people with pancreatic cancer or noncancerous pancreatic disease to compare exosome activity. The goal is to understand …

This observational study follows 200 people with inherited mutations in BRCA1/2, ATM, or PALB2 genes who are already undergoing regular pancreatic cancer screening with endoscopic ultrasound or MRI. Researchers will track how often these imaging tests find pre-cancerous or cancer…

This study is for people with pancreatic cancer. It uses artificial intelligence to find early signs of cachexia, a condition that causes severe weight loss and muscle wasting. Researchers will also see if diet and exercise programs are practical and helpful for patients. The goa…

This study looks at 250 people with pancreatic cancer whose stomach is blocked by the tumor. It compares three procedures—surgery, a metal stent placed by endoscopy, and a newer ultrasound-guided stent—to see which helps patients eat better, maintain weight, and tolerate chemothe…

This study collects blood and leftover tissue samples from 9,600 people with various cancers, including breast, lung, and pancreatic cancer. Researchers will use these samples to improve tests that look for cancer DNA in the blood. The goal is to better detect if cancer returns o…

This study looks at how pancreatic cancer changes over time in people receiving chemotherapy. Researchers take small tissue samples from the tumor at diagnosis and again after treatment to see if the cancer's genetic type has shifted. The goal is to better understand how the canc…

This study is observing 800 people with advanced lung, colorectal, or pancreatic cancer to understand why some lose weight and muscle (cachexia). Researchers hope to find distinct subtypes of cachexia, which could lead to better, more personalized treatments in the future. Partic…

This study will follow 3,000 pancreatic cancer patients in China who are receiving irinotecan liposome II as part of their treatment. Researchers will collect data on side effects, survival, and how well the drug controls the cancer. The goal is to understand how this treatment w…

This study looks back at 168 pancreatic cancer patients who had surgery to remove their tumor. Researchers want to see if changes in uric acid levels after surgery are linked to how long patients live and whether the cancer comes back. The goal is to find out if controlling uric …

This study is testing whether a special type of ultrasound called multiparametric ultrasound (mpUS) can provide more detailed images of tissue than standard ultrasound. Researchers will compare mpUS results with regular tests in up to 85 people who are at high risk for pancreatic…

This study follows 200 people with cancers of the esophagus, stomach, pancreas, colon, or rectum who are scheduled for surgery, along with some healthy controls. Researchers will track weight, muscle mass, physical activity, quality of life, and immune markers over a year to bett…

This study looks at the bacteria living in the mouth and gut of people who may have pancreatic cancer. Researchers want to see if certain germs can help spot the disease earlier or predict how well a patient will do. About 300 adults with a suspicious spot on their pancreas will …

This study tracks 100 cancer survivors aged 18–74 to see how common muscle loss (sarcopenia) and cognitive problems ('chemo brain') are after treatment. Participants undergo physical and mental assessments. The goal is to better understand these long-term side effects and guide p…

This study aims to collect medical history, family history, and blood or urine samples from 10,000 people with or at risk for pancreatic cancer. Researchers will use this information to look for genetic and environmental factors linked to the disease. Participants may also be ask…

This study compares a chatbot to standard care to see which better helps Black cancer survivors learn about and request genetic testing for hereditary cancer. About 428 participants will be randomly assigned to either group. The goal is to reduce disparities in genetic testing an…

This study is testing whether an artificial intelligence (AI) tool can help match cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to…

This study collects samples from 320 people, including those with solid cancers (like lung, colon, or pancreatic cancer) and those undergoing lung cancer screening, to look for cancer cells and DNA in blood, urine, and bone marrow. The goal is to learn how cancer spreads and find…

This study collects and stores tissue and blood samples from people with stomach, esophageal, pancreatic, liver, and other gastrointestinal cancers. The goal is to build a large database of samples and medical information to help researchers understand these cancers better. Parti…

This study follows 4,000 adults aged 30 and older who have at least one pancreatic cyst, a common finding on scans. Researchers will track changes over time using surveys and medical records to see which cysts turn into cancer. The goal is to better tell harmless cysts from dange…

This study looks at whether a quick ultrasound of the thigh muscle can detect muscle loss (sarcopenia) in people who have finished cancer treatment. Researchers will compare the ultrasound results with a standard whole-body scan (DEXA) in 55 adults aged 18-74 with certain cancers…

This study is testing whether an AI-powered mobile app can help assess and improve nutrition in 200 patients who have had surgery for pancreatic cancer. The app collects data on symptoms like pain, appetite, and weight, and uses artificial intelligence to guide follow-up care. Th…

This study is testing whether measuring ctDNA (bits of tumor DNA) in blood or stool can help doctors manage patients with cancers of the digestive tract, including pancreas, colon, and bile duct cancers. Researchers will track survival and see how these markers relate to outcomes…